anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Overview of the Study. This project has four phases. In the first two phases the study team will work to gain an understanding of the sources of meaning, hope, legacy and identity in Latino patients with advanced cancer; and to explore the acceptability and feasibility of applying IMCP to Latinos diagnosed with advanced cancer. A convergent mixed-methods design will be utilized with a sample of 155 Latino patients diagnosed with advanced cancer for the quantitative phase, and a nested cohort of 14-20 for the qualitative phase from two cancer centers in New York City: Memorial Sloan Kettering Cancer Center (MSKCC) and Lincoln Medical and Mental Health Center (LMC), a public hospital localized in a Latino-dense region. We will also recruit eligible cancer patients serviced through Dr. Gany's Intergrated Cancer Care Access Network (ICCAN). The Integrated Cancer Care Access Network (ICCAN) of MSKCC's Immigrant Health and Cancer Disparities Service (IHCD) enrolls patients at eleven hospital-based cancer clinics in New York City with large numbers of immigrant and low-income patients. ICCAN uses bilingual Access Facilitators to assist patients in accessing and utilizing health, social, and financial services. Identified needs of the patients, range from psychosocial support, to health literacy, child care, financial, housing and legal concerns. Patients enrolled to the ICCAN program are actively obtaining support from Access Facilitators throughout their treatment period. Access Facilitator will refer eligible patients to the study team for recruitment.

Before moving to phase 3, we will adapt and transcreate (the source text is rewritten to convey the concepts and achieve the aims of the source text, while accounting for both language and cultural considerations) the manual based on the phase 1 and 2 findings. In the third phase (Key Informant feedback), mental health providers will be interviewed to explore additional needed adaptations. The fourth phase will consist of pre-piloting or interviewing patients to assess the comprehension and acceptability of the adapted intervention.

Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs.
Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
BACKGROUND: Frailty has become an important public health issue. This study was conducted to determine the effect of frailty levels of older individuals on their mental well-being and depression levels.
METHODS: This descriptive cross-sectional study was conducted with a total of 325 older individuals aged 60 years and over. A demographic questionnaire form, the FRAIL Frailty Scale, the Warwick-Edinburgh Mental Well-Being Scale, and the Geriatric Depression Scale-Short Form were used to collect data. Data were evaluated using the SPSS 25.0 package program. Number, percentage, mean, standard deviation, Chi-square, correlation, and multiple regression analyses were used.
RESULTS: The mean age of the older individuals was 69.56 ± 7.75 years, and the variables of age, education level, income status, the person they were living with, regular medication use, forgetting to take medication, urinary incontinence, hospitalisation, and accidents were found to affect both frailty and depression (P < 0.05). There was a positive correlation between frailty and depression (r: 0.460, P < 0.001) and a negative correlation between mental frailty and well-being (r: -0.391, P < 0.001). Socio-demographic variables, depression, and mental well-being had a 40% effect on frailty (P < 0.001).
CONCLUSION: Depression status and mental well-being level are related to frailty, so negativity in one of them negatively affects the other. In line with these results, it is recommended to determine the level of depression and mental well-being of older individuals with high risk of frailty, and according to the results of the research, to provide care and support regarding the predictors affecting frailty.
Coronaviruses have caused three severe epidemics since the start of the 21st century: SARS, MERS and COVID-19. The severity of the ongoing COVID-19 pandemic and increasing likelihood of future coronavirus outbreaks motivates greater understanding of factors leading to severe coronavirus disease. We screened ten strains from the Collaborative Cross mouse genetic reference panel and identified strains CC006/TauUnc (CC006) and CC044/Unc (CC044) as coronavirus-susceptible and resistant, respectively, as indicated by variable weight loss and lung congestion scores four days post-infection. We generated a genetic mapping population of 755 CC006xCC044 F2 mice and exposed the mice to one of three genetically distinct mouse-adapted coronaviruses: clade 1a SARS-CoV MA15 (n=391), clade 1b SARS-CoV-2 MA10 (n=274), and clade 2 HKU3-CoV MA (n=90). Quantitative trait loci (QTL) mapping in SARS-CoV MA15- and SARS-CoV-2 MA10-infected F2 mice identified genetic loci associated with disease severity. Specifically, we identified seven loci associated with variation in outcome following infection with either virus, including one, HrS43, that is present in both groups. Three of these QTL, including HrS43, were also associated with HKU3-CoV MA outcome. HrS43 overlaps with a QTL previously reported by our lab that is associated with SARS-CoV MA15 outcome in CC011xCC074 F2 mice and is also syntenic with a human chromosomal region associated with severe COVID-19 outcomes in humans GWAS. The results reported here provide: (a) additional support for the involvement of this locus in SARS-CoV MA15 infection, (b) the first conclusive evidence that this locus is associated with susceptibility across the Sarbecovirus subgenus, and (c) demonstration of the relevance of mouse models in the study of coronavirus disease susceptibility in humans.
Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
PURPOSE:A laxative consisting Grifola ifrondosa S.F. Gray or a treated material thereof. CONSTITUTION:A laxative obtained by containing powder by pulverizing raw Grifola S.F. Gray (naturally occurring fruit bodies or mycelia of those obtained by cultivation or culture) or pulverizing thoroughly dried Grifola frondosa S.F. Gray. The laxative may be directly administered, but processed into granule, tablet, pill, capsule, etc., as necessary. In formulating, the particle size is 20-60 mesh, preferably 30-40 mesh. The laxative is orally administered in a dose of 1-3g/time, preferably 2-2.5g/time expressed in terms of dried powder of the Grifola frondosa S.F. Gray 2-3 times a day after a meal. An inclination for the stool is aroused almost regularly the following morning and defecation can be readily carried out. EFFECT:The laxative can be continuously used for a long period and accompanying symptoms can also be remitted without causing side effect, e.g. habituation, drug resistance, etc.
Among 3,653 patients treated with sumatriptan nasal spray in active- and placebo-controlled clinical trials, less than 0.4% of patients withdrew for reasons related to adverse events. Table 2 lists adverse events that occurred in worldwide placebo-controlled clinical trials in 3,419 migraineurs. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.

Only events that occurred at a frequency of 1% or more in the sumatriptan nasal spray 20-mg treatment group and were more frequent in that group than in the placebo group are included in Table 2.

Phonophobia also occurred in more than 1% of patients but was more frequent on placebo.

Sumatriptan nasal spray is generally well tolerated. Across all doses, most adverse reactions were mild and transient and did not lead to long-lasting effects. The incidence of adverse events in controlled clinical trials was not affected by gender, weight, or age of the patients; use of prophylactic medications; or presence of aura. There were insufficient data to assess the impact of race on the incidence of adverse events.
The RESCUE END-LOW is a multicentered, prospective, randomized, open-label, blinded end-point (PROBE) study. A total of approximately 272 patients (age ≥ 18 years) in a late window (\>24 hours) with a minor stroke (NIHSS \<6) who experienced an END and the imaging evidence of an occlusion of the Internal Carotid Artery (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1) segment will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content. One group will receive best medical management alone the other group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting. The primary objective is to establish the efficacy of EVT in a late window for patients with LVO and a minor stroke who have experienced an END. The study consists of seven visits including the day of randomization, 24 hours after randomization, 48 hours, 72 hours, 7 days or discharge, and 30 and 90 days. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The primary endpoint is the rate of modified Rankin's scale (mRS) 0-2 at 90 days. The trial is anticipated to last from December 2023 to December 2025 with 272 subjects recruited form about 30 centers in China. All the related investigative organization and individuals will obey the Declaration of Helsinki and Chinese Good Clinical Practice standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study. The trial has been approved by Institutional Review Board (IRB) and Ethics Committee (EC) in Yijishan Hospital, Wannan Medical College.
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin, having high safety for the skin, capable of enduring use for a long period, and consequently, capable of fundamentally improving aging, especially wrinkles caused thereby, and therefore extremely effective for inhibiting the aging.  <P>SOLUTION: This external preparation for skin contains an extract obtained from a leaf of Diospyros Kaki Thunb. or a fruit of Crataeguscuneata Sieb. et. Zucc, so that the external preparation which exhibits moisture retaining properties, accelerates collagen production of a skin fibloblast, increases production of an extracellular matrix, improves firmness and wrinkles of the skin, and therefore has an excellent skin aging inhibitory effect is obtained.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
Immersive virtual-reality stimulation (IVR): 1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks. 1 session lasts 19 minutes.1 session every 2 days for 4 weeks (15 sessions total).
Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
The invention belongs to the technical field of biological medicines, and relates to functions and applications of beta 1 protein in hepatoma cells. Specifically, beta 1 serves as an adhesion molecule to influence invasion and migration of cells in hepatoma; the expression of the beta 1 protein exists in the hepatoma cells, the expression quantity of the beta 1 protein is different in different hepatoma cells, and therefore, the invasion and migration capacities of the cells are different. When the expression quantity of the beta1 protein is high, the invasion and migration capacities of the cells are weak; and when the expression quantity of the beta1 protein is low, the invasion and migration capacities of the cells are strong. Substances such as nucleic acids and polypeptides which influence the expression of the beta 1 protein by taking the beta 1 as the target can influence the invasion and migration capacities of the hepatoma cells. The invasion and migration capacities of the hepatoma cells are reduced by increasing substances such as nucleic acids and protein expressed by beta 1. The applications cover diagnosis, detection, typing and the like of hepatoma by taking the beta 1 as the target as well as design and screening of the nucleic acids, and proteins or other substances serve as targeting anti-hepatoma medicines for hepatoma treatment.
BACKGROUND: Management of cancer patients presenting with an acute coronary syndrome (ACS) may be challenging. In this study, we sought to examine whether and how a concomitant diagnosis of active cancer affects patients' management and outcomes following an event of ACS.
METHODS: We used a retrospective cohort data analysis of patients from the Acute Coronary Syndrome Israeli Survey (ACSIS) carried out between the years 2016-2021 to compare patients with and without a concomitant diagnosis of active cancer.
RESULTS: Of 4913 patients who presented with an ACS, 90 (1.8%) patients had a concomitant active cancer. Cancer patients were older, with a higher prevalence of hypertension and chronic renal failure. The rate of ST-elevation myocardial infarction (STEMI) was similar (40%) between both groups. Cancer patients were less likely to undergo coronary angiography during hospitalization; but once it was performed, the rate of percutaneous coronary intervention was similar. The presence of cancer during an ACS was associated with an increased short- and long-term mortality. In a multivariate analysis, the risk for 1-year mortality remained significantly higher in cancer patient (HR 2.72, 95% CI 1.74-4.24, p < 0.001), and was most prominent in patients presenting with STEMI (HR 5.00, 95% CI 2.40-10.39, p < 0.001). Short- and long-term death rates were also higher in cancer patients after a propensity score matching and adjustment for comorbidities other than cancer.
CONCLUSION: Despite significant advances in oncologic and cardiac care, the presence of active cancer in patients with an ACS is still associated with significantly increased risk for 1-year mortality.
Ceftazidime-avibactam 2.5 grams intravenous (IV) every 8 hours infused over two hours for a duration of 7-14 days, with dose adjustment for renal impairment according to the FDA prescribing information. Patients who have a positive Xpert Carb-R screening test or culture for CRE with metallo-beta-lactamases will receive aztreonam added to ceftazidime-avibactam.
Systems, methods, and computer-readable media for providing clinical information to clinicians are provided. In embodiments, a patient's electronic health record is accessed to identify that a first clinician has requested a consult with a second clinician. Each clinician is associated with a clinician identifier that is identified by a plurality of sensors. A location for both the first and second clinician is received from the plurality of sensors. A determination is made whether the first and second clinicians are near one another. Upon determining that the first and second clinicians are near one another, a notification is presented to the first clinician. Such tracking of clinician location helps avoid missed opportunities and provides efficient communication among clinicians.
Glycosaminoglycan derived from queen Bombus ignitus inhibits in vivo abdominal fat accumulation during a high fat diet, reduces a cholesterol content, and reduces free fatty acid in plasma. Activated partial thromboplastin time (APTT) in plasma is extended, so blood coagulation is prevented and adhesion protein-related laminin existing in a hemangioendothelial part is inhibited. In addition, damage to the protein of blood globulin is inhibited, and lipoperoxide accumulation (MDA amount) of liver cells is inhibited. Moreover, when being seen at a cell level, nitric oxide (NO) is generated in hemangioendothelial cells to ensure vasorelaxation. Furthermore, it has been able to be confirmed that rise of blood pressure caused by a high fat diet can be prevented after the glycosaminoglycan has been administrated to a rat for a month. The glycosaminoglycan derived from queen Bombus ignitus provides a composition for inhibiting lipid accumulation, inhibiting cell membrane adhesive protein attachment, reducing blood pressure, and preventing blood clots.
<P>PROBLEM TO BE SOLVED: To provide a dye composition containing a class 2 hair bleaching agent which bleaches the hair to the 7th stage and at the same time dyes it into one of various color tones in one step.  <P>SOLUTION: This dye is a derivative stable against the bleaching agent for an azo, triaryl methane, thiazine, or nitro dye. Its inactivating or weakly activating chemical group increases the stability of a dye in an alkaline bleaching agent, if it is on the aromatic ring of the dye or if it is bonded to ortho and/or para position in regard to the center of a bonded chromophore or an auxochrome. A dye molecule is liable to be attacked by the bleaching agent and finally decomposed if it lacks an inactive substituent or a weak active substituent at the ortho and/or para position or has a strong active group at the position. The inactivating and protective chemical group may be a nitro, halogen, cyano, carboxy, sulfone, alkyl or aromatic group, and must not be an amino, hydroxy, alkoxy, or alkylamide group.  <P>COPYRIGHT: (C)2007,JPO&INPIT
INTRODUCTION: There are a lack of data describing outcomes and follow-up after hospital discharge for patients with newly diagnosed cirrhosis with complication on index admission. This study examines factors that influence outcomes such as readmission, follow-up, and mortality for patients with newly diagnosed cirrhosis.
METHODS: We conducted a single-center retrospective chart review study of 230 patients with newly diagnosed cirrhosis from January 1st, 2020 through December 31st, 2021. We obtained demographics, clinical diagnoses, admission, and discharge MELD-Na, disposition, mortality, appointment requests rate, appointment show rate, and readmission.
RESULTS: The primary complications on admission were GI bleed (27%), ascites (25.7%), and hepatic encephalopathy (HE) (10.4%). Overall, the median length of stay (LOS) was 6 days, and the readmission rate was 27%. Out of 230 patients, 25 (10.9%) patients died while hospitalized while another 43 (18.6%) died after initial discharge within the two-year study period. Although there was a significant reduction of the MELD-Na from admission to discharge (p < 0.05), admission MELD-Na did not correlate with LOS and discharge MELD-Na did not predict readmission. Patients with HE had the highest median LOS, while patients with ascites had the highest readmission rate. The median time to an appointment was 32 days. When comparing discharge destinations, most patients were discharged to home (63%), to facilities (13.9%), or expired (10.9%). The average appointment show rate was 38.5%, although 70% of patients had appointment requests. Readmission rate and mortality did not differ based on appointment requests. No significant differences in outcomes were observed based on race, sex, or insurance status.
CONCLUSION: New diagnosis of decompensated was found to have high mortality and high readmission rates. Higher MELD-Na score was seen in patients who died within 30 days. Routine appointment requests did not significantly improve readmission, mortality, increase appointment show rate, or decrease time to appointment. A comprehensive and specialized hepatology-specific program may have great benefits after cirrhotic decompensation, especially for those with newly diagnosed cirrhosis.
Iodinated dicarboxylic acid and their salts of formula (I) are new: (where A is aminoacyl; X is a direct bond or a 1-14C hydrocarbon chain opt. interrupted by one or more O or S atoms; R1 and R2 are different and are OH or the gp. R3 and R4 are H or 1-10C alkyl opt. substd. by OH or R3+R4 and the attached N-atom form a heterocyclic ring opt. interrupted by another hetero-atom). They are useful as radiographic contrast agents, preferably for urography, which are of low toxicity and are rapidly eliminated by kidneys.
The negative oxygen ion-containing solid paste comprises 18-22g of glossy privet fruit powder, 13-17g of sweet tea root powder, 25-35g of fructus rosae laevigatae, 45-55g of tortoises shell, 18-22g of Achyranthes aspera L., 18-22g of Elephantopus scaber L., 18-22g of Pogonatherum crinitum, 45-55g of negative oxygen ion powder, 45-55g of far infrared ray nanometer powder and 800-1000g of silica gel. The above components are ground to form powder, the powder is mixed uniformly and the mixture is heated to melt and then is cooled so that gel is formed. The Chinese herbal medicinal ingredients, far infrared ray nanometer powder, negative oxygen ion powder and silica gel are mixed to form solid paste. Through far infrared ray and negative oxygen ion action, the Chinese herbal medicinal ingredients produce good effects. The paste has effects of tonifying kidney and nourishing yin, nourishing liver to improve eyesight, relieving fever, reducing blood pressure and resisting viruses. The solid paste can be used flexibly and conveniently and has a wide application range. The composition of the solid paste and cloth, leather or artificial leather can be used as a cloth material and quilt, pillow, mattress, sofa sleeve and chair sleeve materials and can improve human indoor and vehicle interior environments and viral resistance.